Joachim Eeckhout, Author at Labiotech.eu

About

Founder & Managing Director at Labiotech.eu. While I was studying biotechnology in Paris, I got frustrated by the lack of digital media available for the industry and decided to fix it! I launched Labiotech.eu in 2014 and grew it to the largest community for biotech professionals in Europe! Other than biotech news, I’m also a heavy reader of Sci-Fi and Fantasy.

Articles by Joachim Eeckhout

News and Trends 25 Aug 2014

The new strategy of Novartis to acquire Gamida Cell

The deal for the sale of Gamida Cell to Novartis is back on. Instead of a huge exit in hundreds of millions of dollars, this time the deal is in multiple stages, starting with an injection of several dozen millions of dollars into the company. Gamida Cell, developer of a stem-cell treatment for blood cancer, announced today that it […]

August 25, 2014 - 2 minutesmins - By Joachim Eeckhout

News and Trends 21 Aug 2014

Stemedica International succeed in a pre-clinical trial to treat Alzheimer’s disease with stem cells

Stemedica International, a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. The results demonstrated a greater than 30% decrease in amyloid beta (Abeta) plaques in […]

August 21, 2014 - 2 minutesmins - By Joachim Eeckhout

News and Trends 20 Aug 2014

Danish biotech Forward Pharma files for $200m IPO

Forward Pharma, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares. The number of shares to […]

August 20, 2014 - 1 minutemin - By Joachim Eeckhout

News and Trends 20 Aug 2014

uniQure acquires the gene therapy start-up InoCard

uniQure, a leader in human gene therapy, today announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease. InoCard has developed a novel gene therapy to preclinical proof of concept, for the one-time treatment of congestive heart failure (CHF), a rapidly progressing disease […]

August 20, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 19 Aug 2014

Ablynx gain €2.1m to develop a novel Nanobodies for Ocular applications

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Ablynx today announced that it has been awarded a €2.1 million grant by the Flemish Agency for […]

August 19, 2014 - 2 minutesmins - By Joachim Eeckhout

News and Trends 19 Aug 2014

GSK abandon its joint drug project with Galapagos

According to Reuters, Galapagos, a Belgian biotech group announced that GlaxoSmithKline has stopped a joint drug development project over concerns about adverse effects. In June 2006, Galapagos signed a broad alliance with GSK to discover and develop breakthrough medicines. This multi-target, multi-year alliance runs from target discovery through to delivery of a clinical Proof of Concept. […]

August 19, 2014 - 2 minutesmins - By Joachim Eeckhout

News and Trends 19 Aug 2014

Sanofi buy Mannkind’s inhaled insulin for $925m

Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter […]

August 19, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 19 Aug 2014

ProQR Therapeutics files for a $75m IPO to compete with Vertex Pharmaceuticals

ProQR Therapeutics is a Netherlands-based biotech company focused on developments of drugs to treat genetic disorders. Daniel de Boer, Gerard Platenburg, Dinko Valerio and Henri Termeer (former Genzyme’s CEO) founded the company in May 2012 with the main goal of finding a treatment for cystic fibrosis. ProQR has now expanded to more than 50 employees who are working […]

August 19, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 Aug 2014

Active Biotech and Teva together in a Phase II clinical trial against Huntington’s disease

Active Biotech announced today that its partner Teva Pharmaceutical will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington’s disease. Laquinimod is a once-daily oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed primarily for the treatment of relapsing-remitting multiple sclerosis […]

August 15, 2014 - 1 minutemin - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Joachim Eeckhout

About

Articles by Joachim Eeckhout

The new strategy of Novartis to acquire Gamida Cell

Stemedica International succeed in a pre-clinical trial to treat Alzheimer’s disease with stem cells

Danish biotech Forward Pharma files for $200m IPO

uniQure acquires the gene therapy start-up InoCard

Ablynx gain €2.1m to develop a novel Nanobodies for Ocular applications

GSK abandon its joint drug project with Galapagos

Sanofi buy Mannkind’s inhaled insulin for $925m

ProQR Therapeutics files for a $75m IPO to compete with Vertex Pharmaceuticals

Active Biotech and Teva together in a Phase II clinical trial against Huntington’s disease

Subscribe to our newsletter to get the latest biotech news!